Charlie Foucar

Assistant professor at the University of New Mexico. Interest in leukemia and MDS.

[WolverHeme @WolverHeme]

RIP 7+3 (1973-2025)? Why PARADIGM Doesn't Deliver the Eulogy. Listen to our take on the #PARADIGM #Plenary from #ASH25 @ajperissinotti @Berninini https://t.co/oVQCvnyRYm

[Andres Gomez @GomezDLeonMD]

Trainees beware🚨Meetings like #ASH25 are high-density environments of social validation and external rewards.

Extrinsic goals provide temporary satisfaction, undermine autonomy and have negative psychological effects!

Instead focus on intrinsic goals like personal growth, relationships, and community contribution, you will be proud and need no applause.

[Talha Badar @TalhaBadarMD]

Our traditional #COMMAND_consortium meetup at #ASH25 — always a highlight. So proud of this incredible group. @Dr_RoryShallis @Anand_88_Patel @AlexColtoff @ChenyuLinMD @CharlieFoucar #Ehab_Atallah #Eric_Winer we missed @YasminAbaza

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

The new 2025 @ASH_hematology Guidelines for Treating Newly Diagnosed #AMLsm in Older Adults are now online! 🩸🎗️🩸 We provide 9 critical clinical recommendations mirroring real-time practitioner-patient conversations. @SylvesterCancer @BloodAdvances https://t.co/E9JUa2mML3

[Talha Badar @TalhaBadarMD]

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL https://t.co/RrgvZOafqG #leusm #APL

[WolverHeme @WolverHeme]

LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML. Come listen to @Berninini @ajperissinotti @CharlieFoucar and @Anand_88_Patel nerd out! #leusm #gemtuzumab #aml https://t.co/HYCnHSCgOa

[Talha Badar @TalhaBadarMD]

🚨🚨👉🏾 Latest paper from #COMMAND_consortium in American Journal of Hematology | Blood Research Journal | Wiley Online Library https://t.co/wJtk3GEGpv

Led by @AlexandraRojek and @Anand_88_Patel

#RWD on outcome of RR CBF AML, allo-HCT should be considered to improve outcome.
Venetoclax based therapies are effective.

#leusm

[UChicago Leukemia Program @UChicagoLeuk]

Check out this new article led by @AlexandraRojek & @Anand_88_Patel reporting outcomes in R/R CBF-AML previously treated with intensive chemotherapy!

https://t.co/zvZMXla1hA

[Charlie Foucar @CharlieFoucar]

A master class in BCR::ABL1-like ALL. I learned so much and am humbled by how far we have to go in this disease.

https://t.co/vFUZrMr2lU

[UNM Comprehensive Cancer Center @UNMCCC]

#lobosslamcancer Thanks to the UNM Lobos for hosting us!

[Charlie Foucar @CharlieFoucar]

@FirasElChaer @UVACancerCenter @MiamiCancerInst Congrats! Thanks for coming to Albuquerque for our conference!

[Talha Badar @TalhaBadarMD]

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia https://t.co/luIJYHzAmt
by Dr. Luskin et al. #leusm #ALL

100% CR.

At day 84, 100% of patients achieved complete cytogenetic remission.

At day 84, 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively.

[Andres Gomez @GomezDLeonMD]

AML genomic data pooling between 🇺🇸MARROW consortium 🤝 🇲🇽GTLA led by @LugoMd to clarify the meaning of “hispanic” #ASH24.

Mexicans working together in both sides of the Rio Bravo (Grande)

@NidiaZa07175883 #Leusm

[Andres Gomez @GomezDLeonMD]

Extremely proud of @BloodCellsByAle who was awarded the David M. Goldenberg CRTI award at #ASH24 for her recognition as a CRTI participant who presented the highest scoring abstract of the international category at #ASH24.

The best prize: the tools she has gained along the way

[Ruben A. Mesa, MD @mpdrc]

Excited to run into #AMLSM stars @Anand_88_Patel &amp; our own @MadelynBur22 from @AtriumHealthWFB Comprehensive Cancer Center at #ASH24! @AtriumHealth @LevineCancer @WakeCancer @wakeforestmed @UChicagoLeuk @UCCancerCenter @BKRagonMD

[Talha Badar @TalhaBadarMD]

#ASH24 Another very productive #ASH for COMMAND consortium. Presenting several abstracts on acute leukemia and myeloid disorders #leusm #mdssm #mpnsm @Anand_88_Patel @yasminabaza1 @Dr_RoryShallis @vamkota @AlexColtoff @CharlieFoucar @ChenyuLinMD et al.

[Greg Roloff @RoloffGreg]

Topline results studying brexu-cel in relapsed B-ALL, now out @JCO_ASCO. My thanks to @LoriMuffly and partners from 30+ centers driven to answer ?s in a rare disease space. More to come. @bshah @MoffittNews @UChicagoHemOnc
https://t.co/qTw2NQgDKP

[UNM Comprehensive Cancer Center @UNMCCC]

Today is the Lobo Cancer Challenge! More than 1600 people signed up this year to #uniteagainstcancer

[UNM Comprehensive Cancer Center @UNMCCC]

Thank you KOAT for highlighting our Allogeneic Stem Cell transplant program and telling Ana's story. There's still time to support the state-of-the-art cancer treatments and research at UNMCCC by signing up for the #LoboCancerChallenge #UniteAgainstCancer https://t.co/77X7fncP1S

[Anand Patel @Anand_88_Patel]

The final version of our @e_JHaem paper on intensive chemo strategies in CBF-AML is available! @AlexandraRojek #leusm

-3y OS 70% and 3y EFS 51% for entire cohort
-IC + GO 3y EFS 50%, IC alone 3y EFS 47%, IC + KIT inhibitor 3y EFS 85%

https://t.co/KG1ntvgqqP